ESR1 and neoplasm: A majority of patients (42%) had positive estrogen (ER+) and progesterone (PR+) receptors in tumors (major molecular features), and positive Her2/Neu (HER2+) receptor and triple negative tumor (ER-, PR-, HER2) were found in a minority of patients (15% and 22%, respectively).